On Tuesday, 4D Molecular Therapeutics Inc (NASDAQ: FDMT) was 6.19% up from the session before settling in for the closing price of $10.17. A 52-week range for FDMT has been $2.23 – $12.34.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -9.89%. When this article was written, the company’s average yearly earnings per share was at -9.38%. With a float of $41.39 million, this company’s outstanding shares have now reached $46.77 million.
4D Molecular Therapeutics Inc (FDMT) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward 4D Molecular Therapeutics Inc stocks. The insider ownership of 4D Molecular Therapeutics Inc is 11.38%, while institutional ownership is 80.55%. The most recent insider transaction that took place on Oct 24 ’25, was worth 32,136. In this transaction Chief Legal Officer of this company sold 2,678 shares at a rate of $12.00, taking the stock ownership to the 3,594 shares. Before that another transaction happened on Oct 24 ’25, when Company’s Officer proposed sale 1,816 for $10.00, making the entire transaction worth $18,160.
4D Molecular Therapeutics Inc (FDMT) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.9 earnings per share (EPS) during the time that was less than consensus figure (set at -0.84) by -0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.38% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.75% during the next five years compared to -9.89% drop over the previous five years of trading.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
You can see what 4D Molecular Therapeutics Inc (FDMT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4203.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.94, a number that is poised to hit -0.53 in the next quarter and is forecasted to reach -3.48 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
The latest stats from [4D Molecular Therapeutics Inc, FDMT] show that its last 5-days average volume of 1.26 million was superior to 0.86 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 27.84%.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 82.22%, which indicates a significant increase from 39.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.96 in the past 14 days, which was higher than the 0.57 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.09, while its 200-day Moving Average is $5.54. Now, the first resistance to watch is $11.19. This is followed by the second major resistance level at $11.57. The third major resistance level sits at $12.18. If the price goes on to break the first support level at $10.20, it is likely to go to the next support level at $9.59. The third support level lies at $9.21 if the price breaches the second support level.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
There are 46,702K outstanding shares of the company, which has a market capitalization of 504.38 million. As of now, sales total 40 K while income totals -160,870 K. Its latest quarter income was 20 K while its last quarter net income were -54,660 K.
